Literature DB >> 9816335

Relationship between p21 expression and mutation of the p53 tumor suppressor gene in normal and malignant ovarian epithelial cells.

A A Elbendary1, F D Cirisano, A C Evans, P L Davis, J D Iglehart, J R Marks, A Berchuck.   

Abstract

In many cell types, p53-mediated growth inhibition is dependent on induction of p21, which is an inhibitor of cyclin-dependent kinases that are required for cell cycle progression. Failure of mutant p53 proteins to transactivate p21 may lead to uncontrolled proliferation. Because many ovarian cancers have mutations in the p53 gene, we examined p21 levels in normal and malignant ovarian epithelial cells to determine whether p21 expression is dependent on wild-type p53. Normal ovarian epithelial cells and two ovarian cancer cell lines with wild-type p53 expressed readily detectable levels of p21, whereas in p53 null and mutant cell lines, expression of p21 was diminished strikingly. A correlation between the status of the p53 gene and p21 expression also was noted in 23 primary epithelial ovarian cancers. Normal levels of p21 RNA were seen in 4/7 (57%) cancers with wild-type p53, whereas 14/16 (88%) cancers with mutant p53 had reduced p21 expression (P < 0.05). In addition, we found that lambda-irradiation of normal and malignant ovarian epithelial cells with wild-type, but not mutant, p53 resulted in induction of p21. These data are suggestive that induction of p21 is a feature of p53-mediated growth inhibition in normal ovarian epithelial cells. Conversely, mutation of the p53 gene in ovarian cancers usually is associated with decreased p21 expression. The lack of an absolute correlation between p21 expression and the status of the p53 gene in ovarian cancers is consistent with other studies that have suggested that p21 may also be regulated by p53-independent pathways.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9816335

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  28 in total

1.  Mutant IDH1 Disrupts the Mouse Subventricular Zone and Alters Brain Tumor Progression.

Authors:  Christopher J Pirozzi; Austin B Carpenter; Matthew S Waitkus; Catherine Y Wang; Huishan Zhu; Landon J Hansen; Lee H Chen; Paula K Greer; Jie Feng; Yu Wang; Cheryl B Bock; Ping Fan; Ivan Spasojevic; Roger E McLendon; Darell D Bigner; Yiping He; Hai Yan
Journal:  Mol Cancer Res       Date:  2017-02-01       Impact factor: 5.852

2.  Acquisition of a second mutation of the Tp53 alleles immediately precedes epithelial morphological transformation in ovarian tumorigenicity.

Authors:  Kathy Q Cai; Hong Wu; Andres J Klein-Szanto; Xiang-Xi Xu
Journal:  Gynecol Oncol       Date:  2009-04-16       Impact factor: 5.482

3.  A novel function of RNAs arising from the long terminal repeat of human endogenous retrovirus 9 in cell cycle arrest.

Authors:  Lai Xu; Abdel G Elkahloun; Fabio Candotti; Andrzej Grajkowski; Serge L Beaucage; Emanuel F Petricoin; Valerie Calvert; Hartmut Juhl; Frederick Mills; Karen Mason; Neal Shastri; Josh Chik; Cynthia Xu; Amy S Rosenberg
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

4.  p21WAF1/CTP1 expression and hepatitis virus type.

Authors:  H Wagayama; K Shiraki; T Yamanaka; K Sugimoto; T Ito; K Fujikawa; K Takase; T Nakano
Journal:  Dig Dis Sci       Date:  2001-10       Impact factor: 3.199

5.  Interference with the bromodomain epigenome readers drives p21 expression and tumor senescence.

Authors:  Liana P Webber; Veronica Q Yujra; Pablo A Vargas; Manoela D Martins; Cristiane H Squarize; Rogerio M Castilho
Journal:  Cancer Lett       Date:  2019-06-29       Impact factor: 8.679

6.  The effects of p21 gene C98A polymorphism on development of uterine leiomyoma in southeast Iranian women.

Authors:  Saeedeh Salimi; Azam Hajizadeh; Minoo Yaghmaei; Sodabeh Rezaie; Mahnaz Shahrakypour; Batool Teimoori; Mahboube Parache; Anoosh Naghavi; Mojgan Mokhtari
Journal:  Tumour Biol       Date:  2016-06-23

7.  Hepatocyte p53 ablation induces metabolic dysregulation that is corrected by food restriction and vertical sleeve gastrectomy in mice.

Authors:  Marlena M Holter; Darline Garibay; Seon A Lee; Mridusmita Saikia; Anne K McGavigan; Lily Ngyuen; Elizabeth S Moore; Erin Daugherity; Paul Cohen; Kathleen Kelly; Robert S Weiss; Bethany P Cummings
Journal:  FASEB J       Date:  2019-12-10       Impact factor: 5.191

8.  High-content, high-throughput analysis of cell cycle perturbations induced by the HSP90 inhibitor XL888.

Authors:  Susan K Lyman; Suzanne C Crawley; Ruoyu Gong; Joanne I Adamkewicz; Garth McGrath; Jason Y Chew; Jennifer Choi; Charles R Holst; Leanne H Goon; Scott A Detmer; Jana Vaclavikova; Mary E Gerritsen; Robert A Blake
Journal:  PLoS One       Date:  2011-03-07       Impact factor: 3.240

9.  Iron regulatory protein 2 is a suppressor of mutant p53 in tumorigenesis.

Authors:  Yanhong Zhang; Xiuli Feng; Jin Zhang; Minyi Chen; Eric Huang; Xinbin Chen
Journal:  Oncogene       Date:  2019-07-22       Impact factor: 8.756

10.  Prognostic significance of cyclin E and p53 protein overexpression in carcinoma of the renal pelvis and ureter.

Authors:  M Furihata; Y Ohtsuki; H Sonobe; T Shuin; A Yamamoto; N Terao; M Kuwahara
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.